Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 8/20 | 0.74 |
| ▸ | MME | P08473 | 10/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873241 | 1.00 | MMEL1 (0.74) | MMEL1MMEITGB1ITGA4XDH | |
| SCHEMBL2865977 | 0.80 | MME (0.61) | MMEL1MMEITGB1ITGA4 | |
| SCHEMBL14959402 | 0.79 | MME (0.63) | MMEL1MMEITGB1ITGA4 | |
| SCHEMBL2875506 | 0.78 | MME (1.00) | MMEL1MME | |
| SCHEMBL2875501 | 0.78 | MME (1.00) | MMEL1MME | |
| SCHEMBL2875145 | 0.78 | MMEL1 (0.82) | MMEL1MME | |
| SCHEMBL2875152 | 0.78 | MMEL1 (0.82) | MMEL1MME | |
| SCHEMBL2878314 | 0.77 | MMEL1 (0.74) | MMEL1MMEITGB1ITGA4 | |
| SCHEMBL2875080 | 0.77 | MMEL1 (1.00) | MMEL1MME | |
| SCHEMBL2875091 | 0.77 | MMEL1 (1.00) | MMEL1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ITGB1 2849/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ITGB1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.